CLDN6 and CLDN9 dual targeting antibody drug conjugates for the treatment of ovarian and endometrial cancers.

被引：0
|
作者：
Du, Liang [1 ]
Zhang, Hongyan [1 ]
Jin, Lina [1 ]
Chen, Yali [1 ]
Wan, Tingting [1 ]
Xu, Liuliu [1 ]
机构：
[1] Shanghai Genechem Co Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
912
引用
收藏
页数：1
相关论文
共 26 条
  • [1] Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers
    McDermott, Martina S.
    Gong, Ke Wei
    O'Brien, Neil A.
    Conklin, Dylan
    Hoffstrom, Benjamin
    Lu, Ming
    Zhang, Jun
    Luo, Tong
    Jia, Weiping
    Hong, Jenny J.
    Chau, Kevin
    Davenport, Simon
    Press, Michael F.
    Handly-Santana, Abram
    Brugge, Joan S.
    Drapkin, Ronny
    Glaspy, John A.
    Presta, Leonard
    Slamon, Dennis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers
    O'brien, Neil A.
    McDermott, Martina S.
    Zhang, Jun
    Gong, Ke Wei
    Lu, Ming
    Hoffstrom, Benjamin G.
    Conklin, Dylan
    Luo, Tong
    Chau, Kevin
    Liang, Min
    Donahue, Timothy R.
    Glaspy, John A.
    Presta, Leonard
    Slamon, Dennis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [3] Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
    O'Brien, Neil A.
    McDermott, Martina S. J.
    Zhang, Jun
    Gong, Ke Wei
    Lu, Ming
    Hoffstrom, Benjamin
    Luo, Tong
    Ayala, Raul
    Chau, Kevin
    Liang, Min
    Madrid, Athena M.
    Donahue, Timothy R.
    Glaspy, John A.
    Presta, Leonard
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12) : 1365 - 1375
  • [4] Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors
    McDermott, Martina S. J.
    O'Brien, Neil A.
    Hoffstrom, Benjamin
    Gong, KeWei
    Lu, Ming
    Zhang, Jun
    Luo, Tong
    Liang, Min
    Jia, Weiping
    Hong, Jenny J.
    Chau, Kevin
    Davenport, Simon
    Xie, Bin
    Press, Michael F.
    Panayiotou, Richard
    Handly-Santana, Abram
    Brugge, Joan S.
    Presta, Leonard
    Glaspy, John
    Slamon, Dennis J.
    CLINICAL CANCER RESEARCH, 2023, 29 (11) : 2131 - 2143
  • [5] A peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+T cells for the treatment of pancreatic cancers.
    Liu, Jiajian
    Luan, Y.
    Deng, H.
    Wang, F.
    Wang, C.
    Zhang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16240 - E16240
  • [6] Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
    Patel, M. R.
    Hamilton, E. P.
    Piha-Paul, S. A.
    Henry, J.
    Banerji, U.
    Al Hallak, M. N.
    Okada, H.
    Qian, M.
    Zhang, X.
    Said, N.
    Chatikhine, V.
    Fontana, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S488 - S489
  • [7] FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER
    Konecny, Gottfried
    Hendrickson, Andrea Wahner
    Winterhoff, Boris
    Chander, Cinthiya
    Bilic, Sanela
    Davenport, Simon
    Chung, Adrine
    Miller, Lei-Lani
    Press, Michael
    Letrent, Stephen
    Slamon, Dennis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A67 - A67
  • [8] Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options
    Skowron, Margaretha A.
    Kotthoff, Mara
    Bremmer, Felix
    Ruhnke, Katja
    Parmaksiz, Fatma
    Richter, Annika
    Kueffer, Stefan
    Reuter-Jessen, Kirsten
    Pauls, Stella
    Stefanski, Anja
    Stroebel, Philipp
    Stuehler, Kai
    Nettersheim, Daniel
    MOLECULAR MEDICINE, 2023, 29 (01)
  • [9] Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options
    Margaretha A. Skowron
    Mara Kotthoff
    Felix Bremmer
    Katja Ruhnke
    Fatma Parmaksiz
    Annika Richter
    Stefan Küffer
    Kirsten Reuter-Jessen
    Stella Pauls
    Anja Stefanski
    Philipp Ströbel
    Kai Stühler
    Daniel Nettersheim
    Molecular Medicine, 29
  • [10] First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Machado, A.
    Chander, C.
    Davenport, S.
    Bilic, S.
    Miller, L. L.
    Chung, A.
    Press, M. F.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
123